Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
NTHI.OQ - NeOnc Technologies Holdings Inc
NeOnc Technologies Holdings Inc Phase 1 NEO212-01 Dose Escalation Conference Call
Mar 04, 2026 / 02:00PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, everybody. My name is Doctor Thomas Chen. I'm the founder and CMO of Neon Technologies. I am here to present to you our phase 1 study, which is entitled Safety and Efficacy of Neil 212 in Patients with astrocytoma IDH1 mutants, glioblastoma IDH1 wild type or brain metastases.
--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
And over to the You Good morning.
--------------------------------------------------------------------------------
Unidentified_3 [3]
----------------------------------------------

